BeyondSpring Announces U.S. FDA Acceptance And Priority Review Of New Drug Application For Plinabulin And G-CSF Combination For The Prevention Of Chemotherapy-Induced Neutropenia (CIN)

NEW YORK, June 01, 2021 (GLOBE NEWSWIRE)— BeyondSpring Inc. (the“Company” or“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies,...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news